Value through Innovation17 April 2014

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

24.05.2013

Boehringer Ingelheim and Eli Lilly & Company launch type 2 diabetes educational game, "Complications Combat"

- For Non-U.S. and Non-UK media
22.05.2013

Boehringer Ingelheim responds to FDA warning letter

22.05.2013

Wireless Pill Bottle Wins Healthcare Innovation World Cup

21.05.2013

Phase III results: tiotropium* Respimat® effective in symptomatic asthma patients despite at least ICS†/LABA‡ independent of their age, allergic status, smoking status and bronchodilator response

- For Media outside the U.S., Canada and UK
17.05.2013

Change in the Board of Managing Directors at Boehringer Ingelheim

16.05.2013

ASCO 2013: Boehringer Ingelheim to present highly anticipated new Phase III results for front-runner compounds afatinib* and nintedanib* in first- and second-line NSCLC treatment

16.05.2013

ASCO 2013: New Phase III data reveal targeted treatment with afatinib* or with nintedanib* improves progression-free survival in patients with advanced NSCLC

- For non U.S. Media Only
06.05.2013

Boehringer Ingelheim joins Structural Genomics Consortium - for further research into uncurable diseases

25.04.2013

Boehringer Ingelheim Announces a Strong 2012 Performance in China

24.04.2013

Boehringer Ingelheim consistently continues growth phase in financial year 2012

23.04.2013

Boehringer Ingelheim announces results from one of its HCV Phase III trials:
Investigational compound faldaprevir+ shows high viral cure and early treatment success in treatment-naïve patients with genotype-1
hepatitis C

- For media outside USA, UK and Canada only
02.04.2013

Innovative treatment for canine epilepsy: European approval granted for Boehringer Ingelheim’s Pexion®

26.03.2013

FDA perspective published in the New England Journal of Medicine reinforces safety of Pradaxa® (dabigatran etexilate)

- For media outside of the US, the UK & Canada only
26.03.2013

Boehringer Ingelheim and Eli Lilly and Company announce acceptance of European marketing authorisation application for investigational Type 2 Diabetes treatment empagliflozin*

- EX US & UK Medical Media Only
19.03.2013

Boehringer Ingelheim and Lilly initiate MARLINA-T2D™ clinical trial to evaluate use of Trajenta® (linagliptin) in patients with type 2 diabetes and albuminuria

- For Non-U.S. and Non-U.K. Media
18.03.2013

Boehringer Ingelheim Animal Health sponsors PCV2 research projects with more than 400,000 euro

11.03.2013

American College of Cardiology and Boehringer Ingelheim collaborate to advance physician education with focus on China in 2013

- For Non-US, Non-UK & Non-Canadian Media Only
11.03.2013

Pharmaco-invasive strategy including Metalyse® delivers comparable clinical outcomes to primary PCI for STEMI patients who could not undergo primary PCI within one hour from first medical contact

- For NON-U.S. Media Only